newsfilter
← Latest News
Business Wire·

Catabasis Pharmaceuticals to Host Virtual KOL Event on Edasalonexent and Duchenne Muscular Dystrophy

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will be holding a virtual key opinion leader (KOL) event to discuss edasalonexent, currently in Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD), on Friday, September 11,.2020 at 9:00am ET.